trending Market Intelligence /marketintelligence/en/news-insights/trending/KBtFDiNu3IpwLIzADLDXZw2 content esgSubNav
In This List

Teva seeks US FDA approval for generic version of Novo Nordisk's diabetes drug

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Teva seeks US FDA approval for generic version of Novo Nordisk's diabetes drug

Teva Pharmaceutical Industries Ltd. submitted an abbreviated new drug application to the U.S. FDA to market the generic version of Novo Nordisk A/S' Victoza diabetes drug in the U.S.

Teva believes it is the first applicant to file the application for the drug's generic version. If approved, the company will have 180 days of generic market exclusivity.

The Victoza injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.